OR WAIT null SECS
The contract development and manufacturing organization has invested £30-million (US$42 million) at its Dundalk, Ireland site to offer expanded clinical trial services.
Almac Group announced the completed expansion if its Dundalk, Ireland site in a Jan. 18, 2018 press release. Initially announced in January 2017, the £30-million (US$42 million) investment includes a quality control laboratory, packaging facility for commercial drug products, and a 79,000-ft2 European Distribution Centre for clinical trial supply. The site is scheduled to be fully operational by January 2019.
The site passed Health Products Regulatory Authority (HPRA) inspections of its clinical and pharma services. Subsequently, the company plans to become officially licensed to conduct qualified person batch certification and release for both clinical trial material and commercial drug product from its Dundalk facility. This recent expansion accompanies the existing clinical supply and drug product development operations offered at the company’s main site in Craigavon, Northern Ireland.
“Achieving these successful HPRA inspections is a key milestone. In addition, the announcement today of further expansion will ensure our current and future clients receive a seamless solution with access to the EU [European Union] marketplace,” said Alan Armstrong, CEO and Chairman of Almac Group, in a company press release. “Crucially, this will ensure an uninterrupted service provision through any uncertainty Brexit may bring, and for the future, keeping Almac as a global leader in the life-sciences sector.”
Over the past 18 months, the company has made a series of investments, including the expansion of operational capabilities and new hires in each of its main territories in the United States, Asia, and the United Kingdom.
Source: Almac Group